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Abstract Understand the occurrence and predictors of
respiratory impairment in FSHD. Data from 100 FSHD
patients was collected regarding demographics, genetics,
respiratory status and pulmonary function tests, clinical
manifestations and Clinical Severity Scale (CSS) scores.
Patients were assigned to two severity groups using CSS:
mild (scores\3.5) and moderate/severely affected (scores
C3.5). Forced Vital Capacity (FVC) was classified as
severely impaired if less than 50% of the predicted.
Statistical analysis was performed using IBM SPSS
Statistics 23, tests were two-tailed and the level of signif-
icance set at 5%. Spirometry was available for 94 patients;
41.5% had abnormal results with a restrictive pattern in
38.3% patients. There was a correlation between FVC; CSS
score and D4Z4 fragment length with a higher probability
of severe respiratory involvement in the early onset group,
moderate/severe disease and D4Z4 fragments \18 kb.
Patients with severe respiratory involvement showed a high
prevalence of sleep-disordered breathing. FVC decline
over time was indicative of three progression groups.
Respiratory involvement for both ambulant and non-am-
bulant patients with FSHD is more frequent and severe
than previously suggested. Sleep-disordered breathing is
frequent and negatively influences the respiratory status.
Statistical analysis conducted by: Dr. Sandra Moreira, MD, Centro
Hospitalar Entre Douro e Vouga.
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Annual screening of the respiratory status with spirometry
and clinical assessment is thus warranted in FSHD patients,
even while ambulant.
Keywords Facioscapulohumeral dystrophy  Respiratory
impairment  Restrictive lung function
Introduction
Facioscapulohumeral dystrophy (FHSD) is the third most
common muscular dystrophy, with overall prevalence of
3.2–4.6/100,000 [1, 2]. Despite its typical onset with facial
and shoulder weakness, FSHD shows striking clinical
heterogeneity [3–5]. Early onset tends to be associated with
shorter D4Z4 fragments, faster progression and more sev-
ere phenotype [3, 6, 7].
FSHD results from different mechanisms occurring in
carriers of a permissive 4qA allele that lead to
hypomethylation of the 3.3 kb D4Z4 repeat array in
chromosome 4q35, chromatin relaxation and pathologic
expression of DUX4 [8]. D4Z4 repeat contraction causes
disease in 95% of cases (FSHD1); in 5% (FSHD2) the
mechanism is for most related to mutations in SMCHD1
[3, 8, 9].
Shorter D4Z4 repeat arrays are associated to higher
penetrance and earlier disease onset [7, 10, 11]. Some
studies hinted a negative correlation between the fragment
size and severity of disease [10, 12, 13]; while the asso-
ciation between short arrays and high severity scores is
consistent, longer repeats show a higher variability
[3, 10, 11, 14, 15].
Respiratory involvement (RI) is acknowledged as a rare
manifestation of FSHD [17–22] and is described as mild
and occurring late in the course of the disease, with only
1–3% of the patients requiring non-invasive ventilation
(NIV) [17, 22]. The risk of RI seems higher in patients with
spine deformities, severe disease, weaker proximal lower
limbs and wheelchair dependency [17, 19–23]. Sleep-dis-
ordered breathing (SDB), including hypoventilation syn-
drome (HS) and obstructive sleep apnoeas (OSAS), are
frequent in FSHD patients, may occur early in the course of
the disease and may have a subclinical presentation. There
is apparently no correlation between the presence of SDB
and the disease severity [22, 24, 25].
The aim of this study is to evaluate the frequency and
severity of RI in FSHD, identify predisposing factors for
respiratory failure and reasons for NIV, and characterize
the progression of forced vital capacity (FVC) before and
after NIV, and produce evidence to raise standards of care
in FSHD.
Materials and methods
Patients
The current retrospective study included 100 genetically
confirmed FSHD patients followed at the John Walton
Muscular Dystrophy Research Centre (JWMDRC), for
whom data was collected regarding: age of onset, age of
last assessment, muscle strength, locomotor independency
severity scores according to the CSS [14], spine deformi-
ties, dysphagia, respiratory symptoms, symptoms and type
of SDB and spirometry results over time.
Patients were assigned to two severity groups,
according to the CSS score: mildly affected group scores
\3.5 and moderate/severely affected group scores C3.5.
Males and females were compared in terms of severity
scores and FVC levels. The 10-grade CSS scale was
used taking into account the extent of weakness in
various muscular regions, and considering the spread of
symptoms from face to upper limb, pelvic and leg
muscles. According to this scale [14], higher scores
were ascribed to patients with a more pronounced
involvement of pelvic and proximal lower limb mus-
cles, for this we used the muscle assessments reported
in the patients’ notes.
Genetic confirmation was performed using Southern
blot-based methods for FSHD1 [9] and hypomethylation
screening plus SMCHD1 sequence analysis for FSHD2
[8].
Patients were divided in two groups for age of onset
(data available for 88 patients) using Brouwer’s criteria
[26]: early onset and normal onset. Both groups were
compared for severity scores, frequency of wheelchair
dependency, D4Z4 fragment size and respiratory function.
Duration of the disease was calculated based on age of last
assessment and age of onset.
We have also compared patients with D4Z4 fragments
sizes above or below 18 kb (corresponding to 4-unit frag-
ments) [13], as this cut-off allowed for statistical signifi-
cance in differences between the two groups.
Respiratory function
Respiratory function was assessed through clinical data and
spirometry results (collectively available for 94 patients).
Spirometry was performed using Microlab Care Fusion
portal spirometer with facial mask. Patients with FVC
\80% predicted, normal FEV1/FVC ratio (C70%) and no
symptoms or clear risk of obstructive lung disease were
classified as having a restrictive pattern. Two patients with
a mixed pattern were included in this group given the
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predominant restrictive component. An obstructive pattern
was considered in patients with FEV1\80% and FEV1/
FVC ratio\70% [27, 28]. For further detail on respiratory
function analysis, see supplementary material.
Patients with sustained FVC \50% predicted or with
FVC at the last assessment\50% not explained by an acute
intercurrence, were classified as severe respiratory
involvement group (SR group) and compared to the non-
severe respiratory involvement group with FVC C50%
(NSR group).
Diagnosis of NH (with desaturation or hypercapnia) was
based on overnight pulse oximetry results and arterial
gases. The diagnosis of OSAS was done by polysomnog-
raphy. Symptoms of SDB were considered when patients
complained of excessive daytime sleepiness, snoring,
apnoeas, morning headaches or morning sickness.
Statistical analysis
Demographics and population characteristics were reported
using descriptive statistics. The Chi-square test was per-
formed to assess differences between groups. Independent
samples t test and Kruskal–Wallis test were used to com-
pare means between groups. A logistic regression model
was used and odds ratio calculated to compare the risk of
wheelchair dependency in two different groups of age of
onset.
The correlation between variables (CSS, D4Z4 repeat
size, FVC levels, age of onset and disease duration) was
done using simple linear regression and Pearson’s corre-
lation coefficient (Pearson’s r), provided that residuals
followed normal distribution. Stepwise multiple regression
analysis was used to build a predictive model of FVC
levels. To further assess the risk of having a restrictive
respiratory pattern and severe RI in different groups,
logistic regression models were built and odds ratios
estimated.
Simple linear regression was performed to characterize
FVC decline in SR group, based on the slope of the
regression line of FVC values. Ten out of 14 patients were
considered suitable for this characterization, as they had at
least two FVC measures 3 years apart. Mean of the indi-
vidual slopes was assumed as the mean FVC decline. To
compare FVC progression before and after NIV start,
fourteen patients under NIV (8-SR group; 6-NSR group)
were further analysed through visual analysis of individual
plots of FVC levels.
Statistical tests were two-tailed and the level of signif-
icance was set at 5%. Statistical analysis was performed
using IBM SPSS Statistics 23 for Windows.
Results
Clinical and genetic results
We collected data on 100 genetically confirmed FSHD
patients from 61 families, 54 males and 46 females.
Ninety-seven patients had FSHD type 1 and 3 had FSHD
type 2; in 81/97 we were able to obtain the size of the
D4Z4 fragment, while in the remaining 16 we only had
information on a confirmed pathological range of the
fragment size. The mean age of disease onset (n = 88
patients) was 23.8 ± 15.7 years (23.2 ± 15.3 for
FSHD1 and 39.0 ± 21.8 for FSHD 2, p = 0.336). Six
patients were classified as early onset and 82 as normal
onset. The mean age at the last assessment was
48 ± 16.7 years with mean disease duration of
22.8 ± 15.0 years.
Using CSS, 46 patients were classified as mildly affec-
ted and 54 as moderate/severely affected, 14 of which were
wheelchair bound (supplementary material: Figure S1.a).
There was a positive correlation between the duration of
symptoms and the CSS (r = 0.603, p\ 0.001) (Supple-
mentary material: Figure S1.b). Males and females did not
differ in terms of severity scores (p = 0.273). Distribution
of severity scores in the early onset and normal onset
groups was significantly different (p = 0.021). The early
onset group included a patient with isolated facial weak-
ness, one who walked with assistance (score 4.5) and four
wheelchair-bound patients, which is a significantly higher
proportion than that observed in the normal onset group
(66.7 vs 20.7%, p = 0.028). This translates into a 7.7 times
higher probability of becoming wheelchair dependent in
the early onset group (odds ratio 95% IC 1.3–45.3,
p = 0.025).
Spine deformities, mostly hyperlordosis (n = 13), were
present in 18% of patients; two patients had scoliosis and
kyphosis; one had scoliosis and one kyphosis. The majority
of patients with spine deformities (55.6%) were wheelchair
bound, compared to 19.5% of patients without spine
deformities.
When considering the patients with D4Z4 fragments
\18 kb, a significant linear correlation was found between
the fragment size and both age of onset (r = 0.737,
p = 0.01) (Fig. 1a) and severity scores (r = -0.838,
p\ 0.01) (Fig. 1b). Patients with fragments in this range
showed a higher proportion of early onset when compared
to patients with D4Z4 fragments[18 kb (66.7 vs 33.3%,
p = 0.005). There was no difference in the number of
moderate/severe cases (61.5 vs 58.8%, p = 0.855) in these
two groups.
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Respiratory assessment
Spirometry results were available in 94 patients. There was
no difference in FVC between genders (p = 0.397); 55
patients (58.5%) showed normal spirometry results, 36
(38.3%) had a restrictive pattern and 3 (3.2%) an
obstructive pattern. In 14 patients, FVC levels were\50%
(SR group), corresponding to 14.9% of all patients and to
38.9% of the restrictive pattern group.
A linear correlation was found between the CSS and the
FVC values (r = -0.770, p = 0.03) for patients with
D4Z4 fragments\18 kb (Fig. 2a). Mean FVC was signif-
icantly lower in patients with moderate/severe disease than
with mild disease (mean FVC 69.0 ± 24.5 vs
92.2 ± 15.4%, p\ 0.001), the former had a significantly
higher probability of restrictive lung disease (odds ratio
5.5, 95% IC 2.1–14.5, p = 0.001) and severe RI (odds ratio
12.4, 95% IC 1.5–99.0, p = 0.018). The D4Z4 size showed
a linear correlation with the FVC levels (r = 0.745,
p = 0.005) for fragments\18 kb (Fig. 2b). Compared to
patients with larger fragments, those with fragments
\18 kb had a 4.99 higher probability of having severe RI
(odds ratio 95% IC 1.3–19.3, p = 0.022).
An earlier age of onset showed tendency towards worse
respiratory outcome than the normal onset group (table S2),
as shown by the lower mean FVC values (40.2 ± 31.4 vs
80.0 ± 22.6%, p = 0.026), the higher frequency of
restrictive pattern (83.3 vs 32.9%, p = 0.023) and severe
respiratory compromise (66.7 vs 11.8%, p = 0.005).
Logistic regression showed a 10.29 higher probability of
developing a restrictive pattern (odds ratio 95% IC
1.1–92.0, p = 0.039) and a 14.99 higher probability of
having a drop in FVC below 50% (odds ratio 95% IC
2.4–93.2, p = 0.04) in the early onset compared to the
normal onset group.
A predictive model for FVC decline was built by mul-
tiple regression analysis considering 62 patients with
known age of onset, spirometry results and D4Z4 repeat
size. A significant linear correlation was found between
FVC, severity scores (r = -0.607, p\ 0.001) and D4Z4
fragment size (r = 0.422, p = 0.004) when adjusting for
age of onset (r = 0.205, p = 0.618). The disease duration
Fig. 1 Correlation between D4Z4 fragment size and a age of onset (r = 0.737, p = 0.01) and b Clinical Severity Scale scores (r = -0.838,
p\ 0.01), in patients with fragments up to 18 kb
Fig. 2 a Correlation between CSS scores and FVC (r = -0.770, p = 0.03). b Correlation between D4Z4 fragment size and FVC (r = 0.745,
p = 0.005), in patients with fragments up to 18 kb
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did not improve the predictive model or altered the cor-
relation coefficient of the other variables. Multiple
regression analysis considering only patients with D4Z4
fragments \18 kb showed that the correlation between
fragment size and FVC loses significance when adjusting
for severity, which in turn maintains a significant correla-
tion with FVC (r = -0.846, p = 0.002).
Differences between SR and NSR groups are depicted in
Table 1. Compared to NSR, the SR group showed lower
mean D4Z4 fragment sizes (19.8 ± 6.5 vs 25.7 ± 6.1 kb,
p = 0.008) and a higher proportion of moderate/severe
cases (92.9 vs 51.2%, p = 0.04), higher percentage of
wheelchair-bound patients (71.4 vs 20.0%, p\ 0.001) and
of patients with spine deformities (50.0 vs 13.8%,
p = 0.005), but not of dysphagia (17.5 vs 21.4%,
p = 0.729). Table 2 summarizes respiratory function and
associated comorbidities in patients belonging to the SR
group and in patients with SDB belonging to the NSR
group. Seventeen patients were diagnosed with SDB,
including 13 with NH, two with OSAS and two with NH
and OSAS. One patient with NH with hypercapnia and
another with OSAS were asymptomatic. Compared to
patients without SDB, patients with SDB showed lower
FVC values (45.2 ± 4.1 vs 83.5 ± 2.3%, p\ 0.001),
higher frequency of severe RI (58.8 vs 5.2%, p\ 0.001)
and of moderate/severe cases (100 vs 44.6%, p\ 0.001).
The FVC values over time in ten patients from the SR
group showed a decline that ranged between 1.2 and 12.1%
per year, with a mean of 3.6 ± 3.3% (Fig. 3). The duration
of respiratory follow-up, maximum and minimum recorded
FVC values and percentage of FVC decline per year in
each patient are shown in Table 2. Visual analysis of all the
ten regression lines and their slopes (Fig. 3) suggested
three types of significantly different progression rates
(p = 0.032): a slower FVC decline between 1.2 and 2.1%
per year (mean 1.6 ± 0.3%) (Type 1 progression); a faster
decline between 4.7 and 4.8% per year (mean 4.8 ± 0.1%)
(Type 2 progression); and a single patient who showed an
even faster decline of 12.1% per year over a 4-year period
(Type 3 progression).
Fourteen patients were started on NIV, eight of whom
belonged to the SR group and six to the NSR. FVC values
Table 1 Characteristics of
NSR group and SR group
NSR group SR group p
Respiratory pattern, n = 94
Normal, n (%) 55 (68.8%) 0
Obstructive, n (%) 3 (3.7%) 0
Restrictive, n (%) 22 (27.5%) 14 (100%)
NIV, n (%) 6 8
D4Z4 repeat array, n = 75
Mean (kb) 25.7 ± 6.1 19.8 ± 6.5 0.008
Range (kb) 14–40 11–30
Odds ratio for SRa 4.9 [1.3–19.3] 0.022
11–18 kb, n (%) 7 (11.3%) 5 (38.5%) 0.029
19–40 kb, n (%) 55 (88.7%) 8 (61.5%)
CSS, n = 94
Mild, n (%) 39 (48.8%) 1 (7.1%) 0.004
Moderate to severe, n (%) 41 (51.2%) 13 (92.9%)
Locomotor independency, n = 94
Ambulant, n (%) 64 (80.0%) 4 (28.6%) \0.001
Wheelchair dependent, n (%) 16 (20.0%) 10 (71.4%)
Spine deformities, n = 94
Yes, n (%) 11 (13.8%) 7 (50.0%) 0.005
No, n (%) 69 (86.3%) 7 (50.0%)
Dysphagia, n = 94
Yes, n (%) 14 (17.5%) 3 (21.4%) 0.713
No, n (%) 66 (82.5%) 11 (78.6%)
NSR group (non-severe respiratory involvement) and SR group (severe respiratory involvement) per-
centages in brackets refer to the proportion within each group
NIV non-invasive ventilation, SCC severity clinical score
a Odds ratio refers to probability of severe respiratory involvement in patients with D4Z4 fragments up to
18 kb compared to patients with fragments larger than 18 kb
J Neurol (2017) 264:1271–1280 1275
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in patients under NIV (figures S2.1 to S.15) showed a trend
towards stabilization or even improvement and a trend
towards a new deterioration if NIV was stopped. Mean age
and mean duration of disease at NIV were 50.07 ± 14.5
and 28.6 ± 2.3 years, respectively. An FVC drop to 22%
predicted prompted to start BiPAP in one patient previ-
ously diagnosed with NH that did not tolerate CPAP. In the
remaining patients of the SR group, NIV was started after
acute respiratory failure in 3, after the diagnosis of NH in 3
and after diagnosis of NH and OSAS in one. Two patients
refused NIV despite symptomatic NH. CPAP was initiated
in five patients with SDB belonging to the NSR group; four
had NH and one asymptomatic OSAS. One patient recently
diagnosed with NH with desaturations was due to start
NIV.
Discussion
This study includes the largest FSHD population with
respiratory assessment reported so far. The proportion of
FSHD2 patients is slightly lower than previously reported
[3, 5, 8, 9]. The positive correlation between disease
duration and severity scores confirms the progressive nat-
ure of the disease. In agreement with other studies [3, 7],
we confirmed a higher proportion of wheelchair users in
the early onset group, with a prevalence that is remarkably
high (66.7%) comparing to what was previously reported
(4.2–21%) [7]. Despite the small number of patients with
early onset, the prevalence may even be underestimated, as
18 cases with undetermined age of onset (5 non-ambulant)
were excluded from the analysis.
Our results support previous suggestions that shorter
D4Z4 arrays are associated with an earlier onset [11], as
shown by the higher proportion of early onset cases in
patients with D4Z4 fragments\18 kb. However, the linear
correlation between D4Z4 size and age of onset was only
present when considering fragments \18 kb, with larger
fragments this is more unpredictable.
Overall, patients with shorter fragments did not have
significantly more severe disease than patients with larger
ones, which may reflect the clinical variability and the high
proportion of severe cases that was observed in the latter
group. In the former, we found a significant linear corre-
lation between fragment size and disease severity, which
agrees with previous studies showing that correlation with
severity, is more consistent for shorter repeats, while sub-
jects carrying longer repeats have a high variability in
clinical severity [3, 10, 11, 14–16]. According to the lit-
erature, carriers of D4Z4 fragments [6 units may have
disproportionate low methylation levels depending not
only on the fragment size but also on epigenetic mecha-
nisms, such as co-inheritance of SMCHD1 mutations [11].T
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We may speculate that unidentified disease modifiers may
influence the age of onset and severity of disease, con-
tributing to the clinical variability, especially in patients
carrying larger arrays.
Our results show that RI is more frequent and severe
than previously suggested [17, 20, 21]. Around 40% of our
patients had a reduced respiratory function with a pre-
dominantly restrictive pattern. The prevalence of restrictive
pulmonary involvement (38.3%) was higher than previ-
ously reported [2, 20] and unlike other studies [17, 19, 20]
the respiratory compromise was severe and the use of NIV
(14% of cases) was more frequent [18, 22].
In patients with D4Z4 fragments up to 18 kb, the strong
correlation between fragment size and severity scores
(Fig. 1b) and between severity scores and FVC (Fig. 2a)
suggests that the association of smaller fragments with
lower FVC levels may be explained, at least in part, by its
influence on severity.
Patients in the SR group carried D4Z4 fragments smaller
than patients in the NSR group. The wide range and
overlap of fragment sizes in between groups supports the
weak, yet significant association between size of the
deletion and respiratory function. As shown by the higher
probability of severe RI in patients with fragments\18 kb
(odds ratio 4.9; 95% IC 1.3–19.3, p = 0.022).
Although severity of muscle weakness showed the
strongest correlation with FVC values it is not very infor-
mative in early stages. Early disease onset and D4Z4
fragment size may be more useful as they allow prompt
identification of patients at-risk of RI.
SDB was frequent in our population but the prevalence
may have been underestimated due to the frequent sub-
clinical presentation [24, 25] and insufficient screening of
patients at-risk. Despite the significantly lower mean FVC
in patients with SDB, approximately half of the patients
with NH with desaturations and of those with OSAS still
had FVC [50%, meaning that SDB may occur in the
absence of severe RI, even with FVC levels as high as
70%. Given that all patients with SDB had severity scores
above 3, it would be reasonable to investigate for NH and
OSAS, asymptomatic patients with sustained FVC decline
and lower limbs weakness, in addition to symptomatic
patients regardless.
Analysis of the FVC decline (Fig. 3) in the SR group
suggested three progression rates: slow decline 1.2–2.1%
per year (type 1); fast decline 4.7–4.8% per year (type 2);
and one patient with faster decline of 12.1% per year over a
4-year period (type 3). The slower FVC decline in type 1
cannot be explained by the inclusion of FVC measures
[55% and a hypothetical slower decline in earlier stages of
the disease, as it also included patients with FVC as low as
31%. A faster decline in type 2 and 3 does not seem to be
related to smoking habits, a higher proportion of early
onset cases or lung disease, as these were more frequent in
type 1 (Table 3). The most frequent reason to start NIV
was SDB, followed by acute respiratory failure. NIV
should be started early in the course of the disease, when
patients first have nocturnal hypoventilation (symptomatic
or asymptomatic). This is substantiated by the trend
towards stabilization or increase in FVC values once NIV
is started.
Conclusion
The comprehensive evaluation of a single-centre FSHD
cohort suggests that RI is more frequent and severe than
previously suggested and the restrictive pattern is the most
Fig. 3 FVC decline over time
in patients who developed
severe respiratory involvement
(n = 10). Lines correspond to
individual patient’s FVC
regression lines. Full lines
represent patients with a slower
decline (type 1 progression,
mean decline 1.6 ± 0.3%/year),
spotted lines represent patients
with a faster decline (type 2
progression, mean decline
4.8 ± 0.1%/year) and dashed
line represents a single patient
with an extremely fast decline
(decline 12.1%/year)
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frequent. Although our data suggest three progression rates
of FVC decline, the small number of patients included in
this analysis requires further validation.
Asymptomatic patients are at risk of developing SDB
and acute respiratory failure, and may benefit from a more
proactive screening of respiratory compromise. Patients
should be actively checked for SDB due to its frequency
and the negative effect on respiratory function. Patients
with small D4Z4 arrays, early onset and moderate/severe
disease have a higher risk of RI. Although CSS scores have
the strongest correlation with the risk of RI, array size and
age of onset may be more useful in the clinical practice
allowing an earlier identification of at-risk patients.
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